Biogen Acquires RayThera in $1B Deal
Biogen has agreed to buy secretive startup RayThera for $1 billion, expanding its immunology portfolio. RayThera's mission is to develop safer, more effective therapies for immunological diseases. The deal includes an undisclosed upfront payment and potential $1 billion in milestone payments. Biogen's acquisition marks its latest push into immunology, following a $5.6 billion purchase of Apellis Pharmaceuticals.
Key points
- Biogen is acquiring RayThera, a startup founded in 2023, for $1 billion.
- RayThera's mission is to develop safer, more effective therapies for immunological diseases.
- The deal includes an undisclosed upfront payment and potential $1 billion in milestone payments.
- Biogen's acquisition marks its latest push into immunology, following a $5.6 billion purchase of Apellis Pharmaceuticals.
- RayThera's patents provide clues about the immunology drug candidates being acquired.
Biogen's acquisition of RayThera marks a significant expansion into immunology, a field where the company has traditionally focused on neurology medicines. The deal is worth $1 billion, with an undisclosed upfront payment and potential $1 billion in milestone payments.
RayThera, a startup founded in 2023, has been working on developing safer, more effective therapies for immunological diseases. The company's website is rather opaque, but its patents provide clues about the immunology drug candidates being acquired.
Biogen's acquisition of RayThera is the latest in a series of moves by the company to expand its presence in immunology. In 2022, Biogen acquired Apellis Pharmaceuticals for $5.6 billion, gaining two marketed products and a range of early-stage research projects.
The acquisition is expected to have significant implications for the biotech industry, particularly in the area of immunology. As Biogen continues to push into this field, it will be interesting to see how the company's research and development efforts shape the industry's future.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.